Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015

 With reference to the captioned subject, we wish to inform that, in pursuance to the SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2020, notified by SEBI on July 17, 2020, the Board of Directors of the Company has duly approved the amendments to the Code of Conduct for Prevention of Insider Trading including the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information of the Company ('Insider Trading Code'). The amended insider trading code is also available on the website of the Company at www.biocon.com.
12-08-2020
Bigul

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Investor Meeting
12-08-2020
Bigul

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Investor Meeting
10-08-2020
Bigul

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Investor Meeting
05-08-2020
Bigul

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Investor Meeting
04-08-2020
Bigul

Covid-19: Biocon to amend phase-4 trial protocol for psoriasis drug Itolizumab

 Drug regulator says safety must be main objective; sample size must be increased
03-08-2020
Bigul

BIOCON LTD. - 532523 - Execution Of SHA And SSA With Tata Capital Growth Fund II - Disclosure Pursuant To Regulation 30 Of SEBI Regulations, 2015

 Dear Sir/ Madam, Further to our intimation dated July 31, 2020, in relation to the proposed primary equity investment by Tata Capital Growth Fund II ('Investor') in Biocon Biologics India Limited ('BBIL'), we further inform you that Biocon Limited (the 'Company'), BBIL and the Investor have executed a Share Subscription Agreement ('SSA') and the Company, BBIL, Activ Pine LLP ('Existing Investor') and the Investor have executed a Shareholders' Agreement ('SHA' and together with the SSA, the 'Transaction Documents'). This intimation is being made in compliance with Regulations 30, read with Schedule III and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time ('SEBI Listing Regulations') and the required disclosure is enclosed as Annexure A. We request you to take this on record and that the same be treated as compliance under the applicable regulation(s).
03-08-2020
Bigul

Coronavirus vaccine update: Eyes on India as candidates race towards finish line

 Coronavirus vaccine news update: Biocon founder Kiran Mazumdar-Shaw said that the first doses of the vaccine should be administered to young people and health workers
31-07-2020
Bigul

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Tata Capital Growth Fund to Invest ~USD 30 Million (Rs 225 Crore) in Biocon Biologics for an Equity Stake of 0.85%, Deal Values Biocon Biologics at USD 3.5 Billion.
31-07-2020

Neutral Biocon; target of Rs 450: Motilal Oswal

 Motilal Oswal recommended Neutral rating on Biocon with a target price of Rs 450 in its research report dated July 25, 2020.
28-07-2020
Next Page
Close

Let's Open Free Demat Account